Triple-negative breast cancer (TNBC), defined by the absence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2), represents 12-17% of all breast cancer cases (2). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.